TY  - JOUR
PB  - Elsevier BV
JF  - European Journal of Cancer
A1  - Kroese, Tiuri E
A1  - Bronzwaer, Sebastiaan
A1  - van Rossum, Peter SN
A1  - Schoppman, Sebastian F
A1  - Deseyne, Pieter RAJ
A1  - van Cutsem, Eric
A1  - Haustermans, Karin
A1  - Nafteux, Philippe
A1  - Thomas, Melissa
A1  - Obermannova, Radka
A1  - Mortensen, Hanna R
A1  - Nordsmark, Marianne
A1  - Pfeiffer, Per
A1  - Elme, Anneli
A1  - Adenis, Antoine
A1  - Piessen, Guillaume
A1  - Bruns, Christiane J
A1  - Lordick, Florian
A1  - Gockel, Ines
A1  - Moehler, Markus
A1  - Gani, Cihan
A1  - Liakakos, Theodore
A1  - Reynolds, John V
A1  - Morganti, Alessio G
A1  - Rosati, Riccardo
A1  - Castoro, Carlo
A1  - Cellini, Francesco
A1  - D'Ugo, Domenico
A1  - Roviello, Franco
A1  - Bencivenga, Maria
A1  - de Manzoni, Giovanni
A1  - van Berge Henegouwen, Mark I
A1  - Hulshoff, Maarten CCM
A1  - van Dieren, Jolanda
A1  - Vollebergh, Marieke
A1  - van Sandick, Johanna W
A1  - Jeene, Paul
A1  - Muijs, Christel
A1  - Slingerland, Marije
A1  - Voncken, Francine EM
A1  - Hartgrink, Henk
A1  - Creemers, Geert-Jan
A1  - van der Sangen, Maurice JC
A1  - Nieuwenhuijzen, Grard AP
A1  - Berbee, Maaike
A1  - Verheij, Marcel
A1  - Wijnhoven, Bas
A1  - Beerepoot, Laurens V
A1  - Mohammad, Nadia Haj
A1  - Mook, Stella
A1  - Ruurda, Jelle P
A1  - Kolodziejczyk, Piotr
A1  - Polkowski, Wojciech P
A1  - Wyrwicz, Lucjan
A1  - Alsina, Maria
A1  - Tabernero, Josep
A1  - Pera, Manuel
A1  - Kanonnikoff, Tania F
A1  - Cervantes, Andrés
A1  - Nilsson, Magnus
A1  - Monig, Stefan
A1  - Wagner, Anna D
A1  - Guckenberger, Matthias
A1  - Griffiths, Ewen A
A1  - Smyth, Elizabeth
A1  - Hanna, George B
A1  - Markar, Sheraz
A1  - Chaudry, M Asif
A1  - Hawkins, Maria A
A1  - Cheong, Edward
A1  - van Laarhoven, Hanneke WM
A1  - van Hillegersberg, Richard
A1  - OMEC collaborators
KW  - Esophageal cancer
KW  -  Gastric cancer
KW  -  Metastasectomy
KW  -  Metastasis
KW  -  Oligometastasis
KW  -  Stereotactic body radiotherapy
VL  - 204
N1  - © 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
N2  - INTRODUCTION: The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to provide clinical practice guidelines for the definition, diagnosis, and treatment of esophagogastric oligometastatic disease (OMD). METHODS: Guidelines were developed according to AGREE II and GRADE principles. Guidelines were based on a systematic review (OMEC-1), clinical case discussions (OMEC-2), and a Delphi consensus study (OMEC-3) by 49 European expert centers for esophagogastric cancer. OMEC identified patients for whom the term OMD is considered or could be considered. Disease-free interval (DFI) was defined as the time between primary tumor treatment and detection of OMD. RESULTS: Moderate to high quality of evidence was found (i.e. 1 randomized and 4 non-randomized phase II trials) resulting in moderate recommendations. OMD is considered in esophagogastric cancer patients with 1 organ with ? 3 metastases or 1 involved extra-regional lymph node station. In addition, OMD continues to be considered in patients with OMD without progression in number of metastases after systemic therapy. 18F-FDG PET/CT imaging is recommended for baseline staging and for restaging after systemic therapy when local treatment is considered. For patients with synchronous OMD or metachronous OMD and a DFI ? 2 years, recommended treatment consists of systemic therapy followed by restaging to assess suitability for local treatment. For patients with metachronous OMD and DFI > 2 years, upfront local treatment is additionally recommended. DISCUSSION: These multidisciplinary European clinical practice guidelines for the uniform definition, diagnosis and treatment of esophagogastric OMD can be used to standardize inclusion criteria in future clinical trials and to reduce variation in treatment.
ID  - discovery10191815
UR  - http://dx.doi.org/10.1016/j.ejca.2024.114062
SN  - 0959-8049
Y1  - 2024/06//
TI  - European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)
AV  - public
ER  -